Leukemia News

Severe inflammation among individuals with acute myeloid leukemia limits their bodies’ ability to kill cancerous blood cells, according to study results.

Patient withdrawal from cancer clinical trials can result in systematic bias, insufficiently powered studies and a loss of valuable scientific knowledge, according to a study in JAMA Network Open.

Several clinicians will be honored at this year’s Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for Feb. 15-19 in Orlando.

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research presented at ASH Annual Meeting and Exhibition looking at the use of measurable residual disease to guide treatment of patients with acute myeloid leukemia.

NEW ORLEANS — In this video perspective Richard M Stone, MD, discusses data on the triplet combination regimen of azacitidine with venetoclax and magrolimab.

The risk for suicide remains elevated among individuals diagnosed with cancer compared with the general population, despite a downward trend over the last 2 decades, a recent study found.

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

In a scientific statement, the American Heart Association issued guidance on the epidemiology, diagnosis and management of cancer therapy-induced hypertension.

A year ago, American Red Cross declared the first-ever national blood crisis amid a surge in the omicron variant of COVID-19.